论文部分内容阅读
目的评价氟达拉滨为主方案治疗老年B细胞肿瘤患者的临床疗效及安全性。方法回顾分析12例老年B细胞肿瘤患者经氟达拉滨为主方案治疗的疗效和不良反应。结果 12例患者完成了61个疗程的治疗,总有效率83.3%,CR率41.7%,PR率41.7%;主要不良反应是骨髓抑制和免疫功能抑制。中性粒细胞减少34.4%,血红蛋白下降13.1%,血小板减少13.1%,感染发生率9.8%。结论含氟达拉滨的化疗方案对B细胞肿瘤老年患者疗效较好,耐受性高。
Objective To evaluate the clinical efficacy and safety of fludarabine-based regimen in the treatment of elderly patients with B cell tumor. Methods Retrospective analysis of 12 elderly patients with B-cell carcinoma treated by fludarabine-based programs and adverse reactions. Results Sixteen patients completed 61 courses of treatment with a total effective rate of 83.3%, a CR rate of 41.7% and a PR rate of 41.7%. The main adverse reactions were myelosuppression and immune suppression. Neutropenia 34.4%, hemoglobin decreased 13.1%, thrombocytopenia 13.1%, the incidence of infection 9.8%. Conclusion The chemotherapy regimen containing fludarabine has a good effect on elderly patients with B-cell tumors and is highly tolerant.